ClinicalTrials.gg
CompletedNCT06279533Updated Nov 24, 2025

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules

A Phase 1 interventional study of LV232/Placebo and LV232 in Healthy Subjects, sponsored by Vigonvita Life Sciences. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Vigonvita Life Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is divided into two parts: the safety, tolerability, pharmacokinetic profiles of LV232 capsules after multiple ascending doses (hereinafter referred to as "PK characteristics of multiple ascending doses study ") and food effect study (hereinafter referred to as "FE study"). A total of 48 subjects are planned to be enrolled. The two parts of the study can be carried out simultaneously, and there is no order requirement.

Read the detailed description

PK characteristics of multiple ascending doses study is used randomized, double-blinded, placebo-controlled, single-center design. LV232/Placebo is administered sequentially from low-dose to high-dose and each subject can only orally receive one dose level. There are 3 dose groups (15mg, 40mg and 60mg), 8 subjects will be enrolled in each dose group and the ratio of investigational product to placebo is 3:1. Investigational product is orally administrated QD for day1, day3\~day9. When 7th day visit after last dose (D15) is completed for previous dose group, investigator and sponsor will evaluate the safety and determine whether the next dose group can be started or adjusted.

FE study is a single-center, randomized, open-label, three-period crossover design. 24 healthy subjects divided into 2 groups (20mg、60mg) will be enrolled once all eligibility criteria are met after screening within 14 days prior to investigation product administration. Informed consent should be obtained before any protocol defined procedures can be started.Investigational product administration plan given below: 12 healthy subjects in each group will be randomized to 3 sub-groups, i.e., Group A, Group B, Group C, with 4 subjects in each sub-group. For group A, investigation product will be given after fasting for Period 1, after standard diet for Period 2, and after high-fat diet for Period 3; For group B, investigation product will be given after high-fat diet for Period 1, after fasting for Period 2, and after standard diet for Period 3; For group C, investigation product will be given after standard diet for Period 1, after high-fat diet for Period 2, and after fasting for Period 3. The wash-out period is 5 days.

02

Conditions studied

  • Healthy Subjects

Keywords

  • LV232
  • Phase I
  • dose-escalation
  • Tolerability
  • Pharmacokinetic
  • food effect
03

In context

Lead sponsor

Vigonvita Life Sciences is the lead sponsor of 39 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 45 years old, males or females;
  2. Body weight no less than 50.0 kg for male, no less than 45.0 kg for female, of 19.0 to 26.0kg/m2;
  3. Physical examination, vital signs examination, laboratory examination, examination and B-ultrasound examination results were normal or abnormal without clinical significant;
  4. Subjects who are willing to take effective during the study and within 3 months after the study completed;
  5. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study, and signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with to LV232 or any of the ;
  2. Subjects with allergic diseases or allergic constitution;
  3. Subjects with skin diseases or a history of skin allergies;
  4. Subjects with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, Hematologic System, metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials;
  5. Blood donation or blood loss ≥ 400 mL within 3 months , or have a history of blood product use history
  6. Subjects who have participated in clinical trials of other drugs within 3 months before screening;
  7. Subjects who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health products orally within 2 weeks before screening;
  8. Drug or alcohol addicts within 1 year prior to screening, who drink at least twice a day or more than 14 units per week, or who are addicted to alcohol (1 unit ≈200 mL beer with 5% alcohol content, 25 mL spirits with 40% alcohol content or 85 mL wine with 12% alcohol content);
  9. Subjects who smoked more than 10 cigarettes or equivalent amounts of tobacco a day within one year before screening;
  10. Subjects who can't quit smoking and drinking during the experiment;
  11. Subjects who are positive for virus surface antigen, virus antibody, Treponema pallidum antibody (TPPA) or antibody (Anti-HIV);
  12. Abnormal and chest radiographs (anteroposterior);
  13. B ultrasound examination showed moderate to severe fatty liver;
  14. Pregnant or lactating woman or male subjects whose spouse has a child care plan within 3 months;
  15. The investigator believes that there are other factors that are not suitable for participating in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    PK characteristics of multiple ascending doses study

    There are 24 subjects devided into 3 dose groups (15mg, 40mg and 60mg).8 subjects will be enrolled in each dose group and the ratio of investigational product to placebo is 3:1. LV232/Placebo is administered sequentially from low-dose to high-dose and each subject can only orally receive one dose level. Investigational product is orally administrated QD for day1, day3\~day9. When 7th day visit after last dose (D15) is completed for previous dose group, investigator and sponsor will evaluate the safety and determine whether the next dose group can be started or adjusted.

    Drug: LV232/Placebo

  • Experimental
    FE study

    24 healthy subjects divided into 2 group (20mg and 60mg) will be enrolled once all eligibility criteria are met after screening within 14 days prior to investigation product administration. Informed consent should be obtained before any protocol defined procedures can be started.Investigational product administration plan given below: 12 healthy subjects in each group will be randomized to 3 sub-groups, i.e., Group A, Group B, Group C, with 4 subjects in each sub-group. For group A, investigation product will be given after fasting for Period 1, after standard diet for Period 2, and after high-fat diet for Period 3; For group B, investigation product will be given after high-fat diet for Period 1, after fasting for Period 2, and after standard diet for Period 3; For group C, investigation product will be given after standard diet for Period 1, after high-fat diet for Period 2, and after fasting for Period 3. Wash-out period is 5 days.

    Drug: LV232

Interventions

  • DrugLV232/Placebo

    Drug: LV232 15mg Group: 6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally. Drug: LV232 40mg Group: 6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally. Drug: LV232 60mg Group: 6 subjects will receive LV232 60mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.

    Also known as: LV232 15mg, LV232 40mg, LV232 60mg

  • DrugLV232

    Drug: LV232 20mg Group: 12 subjects will receive LV232 20mg, orally Drug: LV232 60mg Group: 12 subjects will receive LV232 60mg, orally

    Also known as: LV232 20mg, LV232 60mg

06

What researchers measure

Primary outcomes

  1. Tmax

    Maximum observed plasma concentration

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose

  2. Cmax

    Maximum observed plasma concentration

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose

  3. T1/2

    Terminal half life

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose

  4. AUC0-t

    Area under the serum concentration time profile from time zero to the time of the last quantifiable concentration

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose

  5. AUC0-24h

    Area under the serum concentration time profile from time zero to the time of 24h

    Time frame: Calculated using concentration data collected from predose to 24 hours postdose

  6. AUC0-∞

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose

Secondary outcomes

  1. Number of participants with treatment emergent treatment-related adverse event(s)

    Frequency, severity and causal relationship of treatment emergent adverse events

    Time frame: Dosing through follow-up call (7 days after last dose of investigational product)

  2. Laboratory test

    Number of participants with laboratory test findings of potential clinical importance

    Time frame: Dosing through follow-up call (7 days after last dose of investigational product)

  3. Vital signs

    Number of participants with vital signs findings of potential clinical importance

    Time frame: Dosing through follow-up call (7 days after last dose of investigational product)

  4. Number of participants with ECG findings of potential clinical importance

    Number of subjects with change from baseline in electrocardiogram (ECG) parameters

    Time frame: Dosing through follow-up call (7 days after last dose of investigational product)

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Dec 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 28, 2024
StartActual
Feb 27, 2024
Primary completionActual
Dec 17, 2024
CompletionActual
Dec 17, 2024
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06279533
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Feb 27, 2024
Primary completion
Dec 17, 2024
Completion
Dec 17, 2024
Last update
Nov 24, 2025

Study contacts

Chen Yu
principal investigator · Shanghai Xuhui Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LV232

Start the discussion